Go to Top


EDAP TMS SA (EDAP): Submission of PMA Application to the U.S. FDA

EDAP TMS SA (EDAP) is presently accelerating adoption of HIFU therapy as a new standard of care for localized prostate cancer in Europe where the company is the clear market leader while securing US approval through an active FDA Clinical Study at leading urology centers. EDAP announced today the submission of its Pre-Market Approval (PMA) …Read More

pSivida Corp. (NASDAQ:PSDV): Authorization to ILUVIEN in Spain

pSivida (NASDAQ: PSDV) is a leading provider of miniaturized, sustained-release drug delivery products and is continuing the evolution of these systems. PSDV proprietary technologies enable to achieve highly focused, long-term delivery of therapeutics. Company has developed three of the only four products approved by either the US or EU for the long-term, sustained-released delivery of …Read More